Physician profile
Kerry S Lebenger
NPI 1982606471
$76,316.77
in general payments reported to CMS, 2019-2025
13 companies · $10K in 2025
The $10K reported for 2025 was more than what 90% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $8,228 · 2021: $12K · 2022: $12K · 2023: $8,656 · 2024: $5,090 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $1,550 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,535.00 |
| Food and Beverage | $1,550.26 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $32,021.93 | 2019-2023 | Tezspire, Fasenra |
| Optinose US, INC. | $22,303.74 | 2019-2025 | |
| Genzyme Corporation | $7,645.24 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $6,733.91 | 2020-2022 | |
| Ars Pharmaceuticals Operations, INC. | $5,281.17 | 2025 | Neffy |
| Amgen INC. | $1,963.94 | 2022 | |
| Pharming Healthcare, INC. | $123.64 | 2025 | |
| Alk-Abello, INC | $106.12 | 2022 | |
| Genentech USA, INC. | $97.09 | 2024 | Xolair |
| Teva Pharmaceuticals USA, INC. | $17.72 | 2022 | |
| Pfizer INC. | $15.27 | 2024 | |
| Sanofi-Aventis U.S. LLC | $7.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Lebenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.